Co-opting of biological processes opened some of the most fruitful areas of drug discovery, from the wildly successful degraders that utilize the E3 ligase-proteasome pathway to Argenx's Vyvgart that uses FcRn-mediated IgG recycling to treat autoimmune diseases. In this session, panelists will discuss a new generation of approaches that cleverly exploit biological processes -- from novel intra- and extracellular degraders to sequence-specific inhibitors of protein synthesis to pH-engineered ADCs that recycle their targets back to cell surface for more payload pickup.